INVO Fertility Announces First Quarter 2025 Financial Results

Core Viewpoint - INVO Fertility is now exclusively focused on the growing fertility market following the divestiture of a majority stake in NAYA Therapeutics, aiming to expand access to advanced fertility treatments and capitalize on supportive policy shifts in the U.S. [1][3] Financial Performance - Revenue for Q1 2025 was $1,637,185, representing a 4% increase from $1,576,286 in Q1 2024 [6] - Consolidated clinic revenue increased by 5% to $1,621,553 compared to $1,537,199 in the previous year [6] - Total revenue from all clinics, including consolidated and equity method clinics, was $1,943,763, up 4% from $1,869,513 [6] - The net loss for the quarter was $(17.4) million, significantly higher than $(1.6) million in the prior year, primarily due to a non-cash impairment charge of $14.6 million related to NAYA Therapeutics [6][11] - Adjusted EBITDA was $(606,551), compared to $(427,467) in the previous year, excluding losses from NAYA TX [6][7] Strategic Focus - The company has sharpened its focus on its core mission as a fertility company, implementing initiatives to accelerate organic clinic growth and exploring acquisitions for expansion [3][4] - The divestiture of NAYA TX is expected to allow both INVO Fertility and NAYA TX to concentrate on their respective opportunities, with INVO Fertility aiming for cash flow break-even and profitability [4][3] Business Model - INVO Fertility is dedicated to expanding assisted reproductive technology (ART) care, focusing on building, acquiring, and operating fertility clinics, including INVO Centers that offer the intravaginal culture (IVC) procedure [8] - The IVC procedure, enabled by the proprietary INVOcell medical device, provides a more natural and affordable experience compared to traditional IVF, with comparable results at a lower cost [8]